Competitive fluorescence-activated cell sorting (FACS) analysis showed that Tg chimeras 1 and 2 as well as the control chimera retained their antigen-binding activity and inhibited the binding of FITC-labeled anti-CD35 antibody to the CD19+ cells from patients with HT (Figure 3A). This evidence concerns the gene CR1 and hematocrit.